Sandra Pepperl-Klindworth

Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles.

B. Plachter, S. Pepperl-Klindworth, N. Frankenberg, 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA

B. Plachter, S. Pepperl-Klindworth, W. Hinderer, 2001, Journal of medical virology.

The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency.

B. Plachter, A. Cunningham, S. Avdic, 2009, Blood.

Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion.

K. Besold, B. Plachter, M. Theobald, 2007, The Journal of general virology.

Cytomegalovirus interleukin-10 expression in infected cells does not impair MHC class I restricted peptide presentation on bystanding antigen-presenting cells.

K. Besold, B. Plachter, M. Theobald, 2006, Viral immunology.

Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65

B. Plachter, T. Stamminger, Peter Lischka, 2012, Medical Microbiology and Immunology.

Mechanisms of Immunodominance in Human Cytomegalovirus Infection

B. Plachter, S. Pepperl-Klindworth, N. Frankenberg, 2003 .

Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus.

B. Plachter, R. Meyer, S. Pepperl-Klindworth, 2002, Virology.

Protein delivery by subviral particles of human cytomegalovirus

B. Plachter, S. Pepperl-Klindworth, N. Frankenberg, 2003, Gene Therapy.